CN105168373A - Blood fat-reducing glossy privet fruit extract and preparation method thereof - Google Patents
Blood fat-reducing glossy privet fruit extract and preparation method thereof Download PDFInfo
- Publication number
- CN105168373A CN105168373A CN201510579009.7A CN201510579009A CN105168373A CN 105168373 A CN105168373 A CN 105168373A CN 201510579009 A CN201510579009 A CN 201510579009A CN 105168373 A CN105168373 A CN 105168373A
- Authority
- CN
- China
- Prior art keywords
- extract
- alcohol
- ligustri lucidi
- fructus ligustri
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a blood fat-reducing glossy privet fruit extract and a preparation method thereof. The preparation method includes the following steps: (a) by weight, every 100 parts of medicinal materials include 80 to 90 parts of dry mature glossy privet fruits and 10 to 20 parts of dry liquorice, and the medicinal materials are mixed and ground; (b) ethanol is used for heat reflux extraction, and extracts are merged, and are concentrated until no alcohol taste, so that concentrate is obtained; (c) petroleum ether, ethyl acetate and water-saturated n-butyl alcohol are respectively used for extracting the concentrate in step (b), so that petroleum ether extract, ethyl acetate extract and n-butyl alcohol extract are respectively obtained; (d) macroporous resin is used for enriching the n-butyl alcohol extract, 20 to 30 percent of ethanol is first used for flushing for six to eight column volumes to remove polysaccharide, 55 to 65 percent of ethanol is then used for elution for 8 to 10 column volumes, and 55 to 65 percent of ethanol eluent is collected, concentrated by vacuum and spray-dried. The extract has the effect of reducing blood fat.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to Fructus Ligustri Lucidi extract of a kind of blood fat reducing and preparation method thereof.
Background technology
Medical material Fructus Ligustri Lucidi is the fruit of Oleaceae Ligustrum plant Fructus Ligustri Lucidi, has another name called Fructus Ligustri Lucidi real (" herbal classic "), Fructus Ilicis Purpureae (" the anxious celestial being side of Ji "), white beeswax tree (" Chinese medicine shape sex experience differential method "), Mus Chinese catalpa (" Guangxi Chinese medicinal herbal ").
Have another name called former plant Fructus Ligustri Lucidi (formal name used at school: Ligustrumlucidum) Ilicis Purpureae etc., is Oleaceae Ligustrum evergreen shrubs or arbor, Gao Keda 25 meters; Bark taupe.Branch yellowish-brown, Lycoperdon polymorphum Vitt or aubergine, cylindrical, dredge raw circular or Long Circle hole skin.Blade is evergreen, keratin, avette, long avette or oval to wide ellipse, long 6 ~ 17 centimetres, wide 3 ~ 8 centimetres, the sharp point of tip is to gradually sharp or blunt, basal circular or subcircular, sometimes wide wedge shape or gradually narrow, leaf margin is smooth, light above, two sides is without hair, and middle arteries and veins is recessed into above, below protruding, lateral vein 4 ~ 9 is right, and two sides is slightly protruding or sometimes not obvious; Long 1 ~ 3 centimetre of petiole, upper mask ditch, without hair.Panicle top is raw, long 8 ~ 20 centimetres, wide 8 ~ 25 centimetres; Long 0 ~ 3 centimetre of peduncle; Rachis and branch axle without hair, purple or yellowish-brown, fruit tool rib; Inflorescence base portion bract Chang Yuye homotype, squamella lanceolar or linear, long 0.5 ~ 6 centimetre, wide 0.2 ~ 1.5 centimetre, wither and fall; Flower nothing stalk or near without stalk, length is no more than 1 millimeter; Calyx is without hair, and long 1.5 ~ 2 millimeters, tooth is not obvious or closely cut shape; Long 4 ~ 5 millimeters of corolla, corolla pipe range 1.5 ~ 3 millimeters, long 2 ~ 2.5 millimeters of sliver, opisthotonos: the long 1.5-3 millimeter of filigree, flower pesticide Long Circle, long 1 ~ 1.5 millimeter; Long 1.5 ~ 2 millimeters of style, stigma is bar-shaped.Fruit kidney shape or nearly kidney shape, long 7 ~ 10 millimeters, 4 ~ 6 millimeters, footpath, deep blue-black is reddish black time ripe, by white lead; Long 0 ~ 5 millimeter of carpopodium.5 ~ July of florescence, really May in July phase to next year.
Fructus Ligustri Lucidi fruit is medicinal, and mature fruit of gathering is dried after drying or put and scalding in hot water, and Chinese medicine is called Fructus Ligustri Lucidi.Cool in nature, sweet in the mouth, hardship.There is nourishing the liver and kidney, strong waist knee joint, effect of crow palpus improving eyesight.For vertigo and tinnitus, the symptoms such as soreness of the waist and knees, early whitening of beard and hair, poor vision, Hiccough and deaf, early whitening of beard and hair and odontoseisis.
Summary of the invention
The object of the present invention is to provide a kind of Fructus Ligustri Lucidi extract, the preparation method of this extract and liquid phase analysis method, the pharmaceutical preparation containing this extract and utilize this extract to prepare the purposes of blood lipid-lowering medicine.
Above-mentioned purpose of the present invention is achieved by technical scheme below:
A kind of Fructus Ligustri Lucidi extract, this extract is prepared by following methods:
A () by weight, every 100 parts of medical materials comprise dry Fructus Ligustri Lucidi mature fruit 80 ~ 90 parts and 10 ~ 20 parts dry, Radix Glycyrrhizae, co-grinding; B () extracts with alcohol heat reflux, merge extractive liquid, is concentrated into and obtains concentrated solution without alcohol taste; C () uses petroleum ether, ethyl acetate and water saturated n-butanol extraction successively to step (b) concentrated solution, obtain petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract respectively; D () n-butyl alcohol extract macroporous resin enrichment, first with 15 ~ 25% alcohol flushing, 8 ~ 10 column volume removing polysaccharide, then uses 60 ~ 70% ethanol elution, 8 ~ 10 column volumes, collects 60 ~ 70% ethanol elution, concentrating under reduced pressure, spraying dry.
Further, macroporous resin described in step (d) is AB-8 type macroporous resin.
Further, extracting with alcohol heat reflux the concentration of alcohol adopted described in step (b) is 70 ~ 80%.
Further, extracting with alcohol heat reflux the concentration of alcohol adopted described in step (b) is 75%.
Further, step (d) is by n-butyl alcohol extract macroporous resin enrichment, first with 20% alcohol flushing, 9 column volume removing polysaccharide, then uses 65% ethanol elution, 9 column volumes, collects 65% ethanol elution, concentrating under reduced pressure, spraying dry.
In order to be controlled Fructus Ligustri Lucidi extract differences between batches prepared by Different sources, batch medical material by the method setting up HPLC finger printing, the liquid phase analysis method of described extract is:
Chromatographic column: AgilentZorbaxExtentC18 post (4.6mm × 250mm, 5 μm);
Mobile phase: A is methanol, and B is 0.1% aqueous formic acid;
Gradient elution program: 0.01 ~ 5min, A25% ~ 35%; 5 ~ 10min, A35% ~ 50%; 10 ~ 25min, A50%; 25 ~ 26min, A50% ~ 25%; 26 ~ 30min, A25%;
Flow rate of mobile phase: 1.0mLmin
- 1;
Determined wavelength: 280nm;
Column temperature: 30 DEG C;
Sample size: 10 μ L.
Pharmaceutical preparation, the described Fructus Ligustri Lucidi extract containing treatment effective dose and pharmaceutically acceptable carrier.
The application of described Fructus Ligustri Lucidi extract in the medicine of preparation blood fat reducing.
The application of described pharmaceutical preparation in the medicine of preparation blood fat reducing.
When extract of the present invention is used as medicine, directly can uses, or use in the form of a pharmaceutical preparation.
Described pharmaceutical preparation contains the Fructus Ligustri Lucidi extract of the present invention for the treatment of effective dose, and all the other are acceptable on materia medica, nontoxic to humans and animals and pharmaceutically suitable carrier of inertia and/or excipient.
Described pharmaceutically suitable carrier or excipient are that one or more are selected from solid, semisolid and liquid diluent, filler and pharmaceutical preparation adjuvant.Pharmaceutical preparation of the present invention is used with the form of per weight dose.Extract of the present invention is applied to by form that is oral or injection the patient needing treatment.For time oral, tablet, slow releasing tablet, controlled release tablet, capsule, drop pill, micropill, suspensoid, Emulsion, powder or granule, oral liquid etc. can be made into; During for injecting, can be made into aqueous or oily solution, aseptic powder injection, liposome or the Emulsion etc. of sterilizing.
Advantage of the present invention: the present invention by extracting Fructus Ligustri Lucidi, remove impurity, enrichment process, the extract of blood fat reducing can be obtained; Liquid phase analysis method provided by the invention may be used for the finger printing setting up this extract, for controlling Different sources, the differences between batches of extract prepared by batch medical material.
Accompanying drawing explanation
Fig. 1 is Fructus Ligustri Lucidi extract HPLC chromatograms.
Detailed description of the invention
Further illustrate essentiality content of the present invention below in conjunction with embodiment, but do not limit scope with this.Although be explained in detail the present invention with reference to preferred embodiment, those of ordinary skill in the art should be appreciated that and can modify to technical scheme of the present invention or equivalent replacement, and does not depart from essence and the scope of technical solution of the present invention.
Embodiment 1: Fructus Ligustri Lucidi extract preparation (85 parts of Fructus Ligustri Lucidi, 15 portions of Radix Glycyrrhizaes)
Crude drug source: Fructus Ligustri Lucidi and Radix Glycyrrhizae are purchased from Hui nationality's Chinese Medicinal Materials Markets.
Main agents: food-grade ethanol is purchased from Shanghai Ling Feng chemical reagent company limited; Pharmaceutical grade AB-8 macroporous resin is purchased from sky tunami letter resin company limited; Methanol is HPLC level, is purchased from TEDIA; Formic acid is HPLC level, is purchased from TEDIA; Chromatographic grade pure water is heartily pure water.
By the Fructus Ligustri Lucidi mature fruit of 8.5kg drying and the dry Radix Glycyrrhizae co-grinding of 1.5kg, extract (25L × 3 time) with 75% alcohol heat reflux, merge extractive liquid, is concentrated into and obtains concentrated solution (6L) without alcohol taste, petroleum ether (6L × 3 time) is used successively to concentrated solution, ethyl acetate (6L × 3 time) and water saturated n-butyl alcohol (6L × 3 time) extraction, obtain petroleum ether extract respectively, acetic acid ethyl ester extract and n-butyl alcohol extract 285g, with AB-8 macroporous resin (2kg after n-butyl alcohol extract dissolves with 5L distilled water, column volume 1.5L) enrichment, first use 20% alcohol flushing, 9 column volumes (12L), use 65% ethanol elution, 9 column volumes (15L) again, collect 65% eluent, concentrating under reduced pressure, spraying dry obtains Fructus Ligustri Lucidi extract extract powder and is about 155g.
Embodiment 2: 2. Fructus Ligustri Lucidi extract is prepared (80 parts of Fructus Ligustri Lucidi, 20 portions of Radix Glycyrrhizaes)
Preparation method: by the Fructus Ligustri Lucidi mature fruit of 8.0kg drying and the dry Radix Glycyrrhizae co-grinding of 2.0kg, extract (25L × 3 time) with 75% alcohol heat reflux, merge extractive liquid, is concentrated into and obtains concentrated solution (6L) without alcohol taste, petroleum ether (6L × 3 time) is used successively to concentrated solution, ethyl acetate (6L × 3 time) and water saturated n-butyl alcohol (6L × 3 time) extraction, obtain petroleum ether extract respectively, acetic acid ethyl ester extract and n-butyl alcohol extract 285g, with AB-8 macroporous resin (2kg after n-butyl alcohol extract dissolves with 5L distilled water, column volume 1.5L) enrichment, first use 20% alcohol flushing, 9 column volumes (12L), use 65% ethanol elution, 9 column volumes (15L) again, collect 65% eluent, concentrating under reduced pressure, spraying dry obtains Fructus Ligustri Lucidi extract extract powder and is about 155g.
Embodiment 3: 3. Fructus Ligustri Lucidi extract is prepared (90 parts of Fructus Ligustri Lucidi, 10 portions of Radix Glycyrrhizaes)
Preparation method: by the Fructus Ligustri Lucidi mature fruit of 9.0kg drying and the dry Radix Glycyrrhizae co-grinding of 1.0kg, extract (25L × 3 time) with 75% alcohol heat reflux, merge extractive liquid, is concentrated into and obtains concentrated solution (6L) without alcohol taste, petroleum ether (6L × 3 time) is used successively to concentrated solution, ethyl acetate (6L × 3 time) and water saturated n-butyl alcohol (6L × 3 time) extraction, obtain petroleum ether extract respectively, acetic acid ethyl ester extract and n-butyl alcohol extract 285g, with AB-8 macroporous resin (2kg after n-butyl alcohol extract dissolves with 5L distilled water, column volume 1.5L) enrichment, first use 20% alcohol flushing, 9 column volumes (12L), use 65% ethanol elution, 9 column volumes (15L) again, collect 65% eluent, concentrating under reduced pressure, spraying dry obtains Fructus Ligustri Lucidi extract extract powder and is about 155g.
Embodiment 4: 4. Fructus Ligustri Lucidi extract is prepared (75 parts of Fructus Ligustri Lucidi, 25 portions of Radix Glycyrrhizaes)
Preparation method: by the Fructus Ligustri Lucidi mature fruit of 7.5kg drying and the dry Radix Glycyrrhizae co-grinding of 2.5kg, extract (25L × 3 time) with 75% alcohol heat reflux, merge extractive liquid, is concentrated into and obtains concentrated solution (6L) without alcohol taste, petroleum ether (6L × 3 time) is used successively to concentrated solution, ethyl acetate (6L × 3 time) and water saturated n-butyl alcohol (6L × 3 time) extraction, obtain petroleum ether extract respectively, acetic acid ethyl ester extract and n-butyl alcohol extract 285g, with AB-8 macroporous resin (2kg after n-butyl alcohol extract dissolves with 5L distilled water, column volume 1.5L) enrichment, first use 20% alcohol flushing, 9 column volumes (12L), use 65% ethanol elution, 9 column volumes (15L) again, collect 65% eluent, concentrating under reduced pressure, spraying dry obtains Fructus Ligustri Lucidi extract extract powder and is about 155g.
Embodiment 5: 5. Fructus Ligustri Lucidi extract is prepared (95 parts of Fructus Ligustri Lucidi, 5 portions of Radix Glycyrrhizaes)
Preparation method: by the Fructus Ligustri Lucidi mature fruit of 9.5kg drying and the dry Radix Glycyrrhizae co-grinding of 0.5kg, extract (25L × 3 time) with 75% alcohol heat reflux, merge extractive liquid, is concentrated into and obtains concentrated solution (6L) without alcohol taste, petroleum ether (6L × 3 time) is used successively to concentrated solution, ethyl acetate (6L × 3 time) and water saturated n-butyl alcohol (6L × 3 time) extraction, obtain petroleum ether extract respectively, acetic acid ethyl ester extract and n-butyl alcohol extract 285g, with AB-8 macroporous resin (2kg after n-butyl alcohol extract dissolves with 5L distilled water, column volume 1.5L) enrichment, first use 20% alcohol flushing, 9 column volumes (12L), use 65% ethanol elution, 9 column volumes (15L) again, collect 65% eluent, concentrating under reduced pressure, spraying dry obtains Fructus Ligustri Lucidi extract extract powder and is about 155g.
Embodiment 6: liquid-phase chromatographic analysis
Need testing solution is prepared: in the brown volumetric flask of extract extract powder 5mg to 50mL that Example 1 method is obtained, add 30mL25% methanol aqueous solution ultrasonic dissolution, after being cooled to room temperature, continue to add 25% methanol aqueous solution standardize solution.
Analytical method:
High performance liquid chromatograph: Agilent1100, binary pump;
Chromatographic column: AgilentZorbaxExtentC18 post (4.6mm × 250mm, 5 μm);
Mobile phase: A is methanol, and B is 0.1% aqueous formic acid;
Gradient elution program: 0.01 ~ 5min, A25% ~ 35%; 5 ~ 10min, A35% ~ 50%; 10 ~ 25min, A50%; 25 ~ 26min, A50% ~ 25%; 26 ~ 30min, A25%;
Flow rate of mobile phase: 1.0mLmin
-1;
Determined wavelength: 280nm;
Column temperature: 30 DEG C;
Sample size: 10 μ L.
Analyze the extract prepared with 10 batches of Different sources, batch Fructus Ligustri Lucidi, set up finger printing and mate, 1 ~ No. 10 peak all occurs in 10 batch sample chromatograms as a result.Therefore demarcate 10 peaks for total fingerprint peaks, set up the HPLC finger printing of this extract accordingly, the results are shown in Figure 1.
Embodiment 7: Fructus Ligustri Lucidi extract pharmacological testing
One, material
1.1 tested materials and reagent: Fructus Ligustri Lucidi extract 1. ~ 5. obtain according to embodiment 1 ~ 5 respectively, make suspension before test, the used time shakes up.Positive drug Xuezhikang (Beijing WBL Peking University Biotech Co., Ltd, lot number 20071116).Propylthiouracil Tablets (Guangdong Huanan Pharmaceutical Co., Ltd, lot number 070701).Cholesterol (Beijing Xia Si Bioisystech Co., Ltd, Amresco subpackage product, article No. 0433).No. 3, cholate (Chemical Reagent Co., Ltd., Sinopharm Group, lot number F20061205).Pentobarbital sodium (Beijing chemical reagents corporation, lot number 020919).Trisodium citrate (Tianjin Chemical Reagents Factory No.1, lot number 960911).
1.2 animals: SD rat, body weight 180 ~ 200g, male, purchased from Beijing Vital River Experimental Animals Technology Co., Ltd..Animal productiong credit number SCXK (capital) 2007-0001.
1.3 instruments: Microlab300 biochemical instruments (Dutch Vitalscien-tific company); 3K15 desk type multifunctional High speed refrigerated centrifuge (German SIGMA company); BT-300 type hemorheology tester (Beijing Bo Laite medical science company limited); LG-PABER-I type platelet aggregation thrombin analyser (Beijing Steellex Scientific Instrument Company).
Two, method
The preparation of 2.1 lipomuls: emulsion formulations is Adeps Sus domestica 15%+ cholesterol 6%+ cholate No. 3 2%+ propylthiouracil 0.2%.Take 75g Adeps Sus domestica to melt in 40 DEG C of water-baths, get to join in Adeps Sus domestica together with 30g cholesterol after 1g Propylthiouracil Tablets is ground to fine powder in mortar and use glass rod stirring and dissolving, add suitable quantity of water, stir, add 10g cholate, add 30mL polyoxyethylene sorbitan monooleate dehydration (Tween 80) again, constantly stir until emulsion produces, then preprepared 37 DEG C of water are slowly added to 500mL and be namely prepared into stable lipomul.Put into Refrigerator store stand-by, use in preposition 37 DEG C of water-baths and melt.
The foundation of 2.2 hyperlipemia model: SD rat 198,180 ~ 200g, male, be divided into 18 groups at random, be respectively normal group, model group, positive control drug Xuezhikang 0.24gkg
-1group, and Fructus Ligustri Lucidi extract 1. ~ 5. low middle high dose group (0.6,1.2,2.4gkg
-1), often organize 11.Except normal group gives drinking water, each group rat is all with 10mLkg
-1dosage gavage lipomul, every day 1 time, continuous 3 weeks.
2.3 medications: SD rat, make in hyperlipidemia model after gavage lipomul 2d, start administration.In morning every day, except Normal group is to except clear water, each group rat continues with 10mLkg
-1dosage gavage lipomul; In afternoon, each administration group is to Fructus Ligustri Lucidi extract, and high, medium and low dosage group dosage is respectively 2.4,1.2,0.6gkg
-1, administration capacity is 20mLkg
-1.Positive drug Xuezhikang 0.24gkg
-1, administration capacity 10mLkg
-1.Normal group and model group give drinking water.All adopt gastric infusion, successive administration 3 weeks.
2.4 Testing index: Rat Fast 12h, 1h after last administration, the eye corner of the eyes gets blood, centrifuging and taking determination of serum TG, TC, LDL-C, HDL-C.Then lumbar injection pentobarbital sodium 45mgkg
-1abdominal aortic blood after anesthesia, 3.8% sodium citrate 1:9 anticoagulant, whole blood viscosity is measured on hemorheology tester, afterwards by whole blood centrifuging and taking blood plasma, measure Plasma Viscosity, and on platelet aggregation thrombin analyser, measure prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT) and fibrinogen content (FIB).
2.5 statistical analysis: data are through homogeneous analysis and normal distribution-test, and adopt SPSS10.0 statistical software to carry out statistical analysis to experimental data, result x ± s represents, compare and adopt t inspection between group.P<0.05 represents that difference has significance.
Three, result
3.1 Fructus Ligustri Lucidi extracts are on the impact of blood lipid level
Result shows, and model group compares with normal group, and TG, TC, LDL-C and HDL-C all obviously raise, and has significant difference (P<0.01), shows that gavage lipomul makes the success of experimental hyperlipemia in rats model.Compare with model group, positive control Xuezhikang group effectively can reduce TG, TC, LDL-C level, and raise HDL-C level, difference has significant (P<0.01, P<0.05); Fructus Ligustri Lucidi extract 1. ~ 3. high dose group obviously can reduce TG, TC level, raise HDL-C level, difference has significant (P<0.01, P<0.05), LDL-C is had to the trend of downward, but difference do not have statistical significance; Fructus Ligustri Lucidi extract 1. ~ 3. in dosage group TG is had to the effect of downward, HDL-C is had to the effect of rising, and has significant difference (P<0.01); Fructus Ligustri Lucidi extract 1. ~ 3. the low dose of impact of group on blood lipid level is not obvious; Fructus Ligustri Lucidi extract 4. ~ 5. each dosage group to the effect of TG, TC, HDL-C and LDL-C and model group without significant difference, on the impact of blood lipid level not obvious (table 1, note: compare with blank group
1)p<0.01,
2)p<0.05; Compare with model group
3)p<0.01,
4)p<0.05, lower same).
Table 1 Fructus Ligustri Lucidi extract is on the impact (x ± s, n=11) of hyperlipidemia rats blood lipid level
| Group | Dosage/gkg -1 | TG | TC | LDL-C | HDL-C |
| Normal group | - | 0.25±0.07 | 1.99±0.43 | 0.73±0.13 | 1.10±0.17 |
| Model group | - | 0.75±0.15 1) | 6.53±1.14 1) | 2.35±0.49 1) | 2.19±0.51 1) |
| Positive drug group | 0.24 | 0.36±0.06 3) | 3.88±1.25 3) | 1.94±0.50 4) | 2.82±0.25 3) |
| Extract is low dose group 1. | 0.6 | 0.77±0.19 | 6.59±1.90 | 2.53±0.64 | 2.75±0.60 4) |
| Extract is middle dosage group 1. | 1.2 | 0.50±0.16 3) | 6.05±1.65 | 2.23±0.65 | 3.14±0.47 3) |
| Extract is high dose group 1. | 2.4 | 0.42±0.10 3) | 5.13±1.80 4) | 2.14±0.47 | 3.26±0.46 3) |
| Extract is low dose group 2. | 0.6 | 0.79±0.21 | 6.73±1.93 | 2.61±0.66 | 2.73±0.63 4) |
| Extract is middle dosage group 2. | 1.2 | 0.52±0.15 3) | 6.07±1.68 | 2.27±0.68 | 3.12±0.45 3) |
| Extract is high dose group 2. | 2.4 | 0.44±0.12 3) | 5.15±1.78 4) | 2.16±0.49 | 3.24±0.47 3) |
| Extract is low dose group 3. | 0.6 | 0.78±0.18 | 6.68±1.88 | 2.52±0.69 | 2.74±0.58 4) |
| Extract is middle dosage group 3. | 1.2 | 0.51±0.14 3) | 6.09±1.64 | 2.25±0.63 | 3.11±0.49 3) |
| Extract is high dose group 3. | 2.4 | 0.45±0.09 3) | 5.14±1.82 4) | 2.17±0.45 | 3.25±0.44 3) |
| Extract is low dose group 4. | 0.6 | 0.76±0.16 | 6.78±1.91 | 2.59±0.61 | 2.21±0.56 |
| Extract is middle dosage group 4. | 1.2 | 0.72±0.15 | 6.63±1.59 | 2.42±0.54 | 2.25±0.51 |
| Extract is high dose group 4. | 2.4 | 0.69±0.11 | 6.47±1.74 | 2.37±0.48 | 2.29±0.48 |
| Extract is low dose group 5. | 0.6 | 0.78±0.17 | 6.83±1.90 | 2.55±0.62 | 2.22±0.54 |
| Extract is middle dosage group 5. | 1.2 | 0.74±0.13 | 6.68±1.52 | 2.41±0.57 | 2.27±0.52 |
| Extract is high dose group 5. | 2.4 | 0.70±0.12 | 6.50±1.77 | 2.35±0.49 | 2.30±0.51 |
3.2 Fructus Ligustri Lucidi extracts are on the impact of whole blood viscosity and Plasma Viscosity
Result shows, and whole blood viscosity and the Plasma Viscosity compared with normal group of model group all have obvious rising, and difference has significance (P<0.01, P<0.05).Compare with model group, Xuezhikang group and Fructus Ligustri Lucidi extract 1. ~ 3. high dose group all effectively can reduce whole blood viscosity, and there is significant difference (P<0.01, P<0.05), in, the whole blood viscosity that causes high lipoprotein emulsion of low dose group raises also certain reducing effect; Meanwhile, 3 dosage groups all can reduce Plasma Viscosity, and difference has significant (P<0.01, P<0.01, P<0.05); Fructus Ligustri Lucidi extract 4. ~ 5. the whole blood viscosity of each dosage group and Plasma Viscosity comparatively model group all there is no significant difference.The results are shown in Table 2.
Table 2 Fructus Ligustri Lucidi extract is on the impact (x ± s, n=11) of hyperlipidemia rats whole blood viscosity, Plasma Viscosity
3.3 Fructus Ligustri Lucidi extracts are on the impact of plasma coagulation factors
Result shows, model group compared with normal group, and activated partial thromboplastin time has obvious shortening, and fibrinogen content significantly raises, and both all have significant difference (P<0.05, P<0.01); Compare with model group, Xuezhikang group and Fructus Ligustri Lucidi extract 1. ~ 3. high dose group can extend activated partial thromboplastin time, reduce fibrinogen content, both all have significant (P<0.01 at difference, and high dose group effect is better than Xuezhikang group P<0.05); With model group ratio, the impact of each administration group on prothrombin time and thrombin time is not obvious.Fructus Ligustri Lucidi extract 4. ~ 5. each dosage group is compared with model group, all not obvious on the impact of activated partial thromboplastin time, fibrinogen content, prothrombin time and thrombin time, does not all have significant difference.The results are shown in Table 3.
Table 3 Fructus Ligustri Lucidi extract is on the impact (x ± s, n=11) of hyperlipidemia rats plasma coagulation factors
This experiment shows, Fructus Ligustri Lucidi extract high dose group can reduce blood lipid level, blood viscosity, the fibrinogen content of experimental atherosclerosis rats, improve blood circulation, suppress the change because of the blood coagulation system index that blood fat raises and lipid metabolic disorder causes, make blood be in low glutinous, hypocoagulability, prevent venothrombotic formation.But its effect is relevant with the content of Radix Glycyrrhizae in Fructus Ligustri Lucidi extract, the two only above-mentioned effect of competence exertion in certain proportion.
Embodiment 8: the preparation of tablet
By embodiment 1 method first obtained extract, add excipient, pelletizing press sheet in itself and excipient weight than the ratio for 1:8.
Embodiment 9: the preparation of oral liquid
By embodiment 1 method first obtained extract, oral liquid method for making makes oral liquid routinely.
Embodiment 10: the preparation of capsule or granule
By embodiment 1 method first obtained extract, add excipient in itself and excipient weight than the ratio for 1:9, make capsule or granule.
Embodiment 11: the preparation of injection
Obtain extract by embodiment 1 method, inject with water, fine straining, injection is made in embedding sterilizing.
Embodiment 12: the preparation of aseptic powder injection
By embodiment 1 method first obtained extract, be dissolved in sterile water for injection, stirring makes molten, filters with aseptic suction funnel, more aseptic fine straining, and be sub-packed in ampoule, after frozen drying, aseptic sealing by fusing obtains injectable powder.
The effect of above-described embodiment is essentiality content of the present invention is described, but does not limit protection scope of the present invention with this.Those of ordinary skill in the art should be appreciated that and can modify to technical scheme of the present invention or equivalent replacement, and does not depart from essence and the protection domain of technical solution of the present invention.
Claims (9)
1. a Fructus Ligustri Lucidi extract, is characterized in that described extract is prepared by following methods: (a) by weight, every 100 parts of medical materials comprise dry Fructus Ligustri Lucidi mature fruit 80 ~ 90 parts and 10 ~ 20 parts dry, Radix Glycyrrhizae, co-grinding; B () extracts with alcohol heat reflux, merge extractive liquid, is concentrated into and obtains concentrated solution without alcohol taste; C () uses petroleum ether, ethyl acetate and water saturated n-butanol extraction successively to step (b) concentrated solution, obtain petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract respectively; D () n-butyl alcohol extract macroporous resin enrichment, first with 15 ~ 25% alcohol flushing, 8 ~ 10 column volume removing polysaccharide, then uses 60 ~ 70% ethanol elution, 8 ~ 10 column volumes, collects 60 ~ 70% ethanol elution, concentrating under reduced pressure, spraying dry.
2. extract according to claim 1, is characterized in that: macroporous resin described in step (d) is AB-8 type macroporous resin.
3. extract according to claim 1, is characterized in that: extracting with alcohol heat reflux the concentration of alcohol adopted described in step (b) is 70 ~ 80%.
4. extract according to claim 3, is characterized in that: extracting with alcohol heat reflux the concentration of alcohol adopted described in step (b) is 75%.
5. extract according to claim 1, it is characterized in that: step (d) is by n-butyl alcohol extract macroporous resin enrichment, first with 20% alcohol flushing, 9 column volume removing polysaccharide, use 65% ethanol elution, 9 column volumes again, collect 65% ethanol elution, concentrating under reduced pressure, spraying dry.
6. extract according to claim 1, is characterized in that: the liquid phase analysis method of described extract is:
Chromatographic column: AgilentZorbaxExtentC18 post (4.6mm × 250mm, 5 μm);
Mobile phase: A is methanol, and B is 0.1% aqueous formic acid;
Gradient elution program: 0.01 ~ 5min, A25% ~ 35%; 5 ~ 10min, A35% ~ 50%; 10 ~ 25min, A50%; 25 ~ 26min, A50% ~ 25%; 26 ~ 30min, A25%;
Flow rate of mobile phase: 1.0mLmin
-1;
Determined wavelength: 280nm;
Column temperature: 30 DEG C;
Sample size: 10 μ L.
7. pharmaceutical preparation, is characterized in that: the extract according to claim 1 containing treatment effective dose and pharmaceutically acceptable carrier.
8. the application of extract according to claim 1 in the medicine of preparation blood fat reducing.
9. the application of pharmaceutical preparation according to claim 7 in the medicine of preparation blood fat reducing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510579009.7A CN105168373A (en) | 2015-09-13 | 2015-09-13 | Blood fat-reducing glossy privet fruit extract and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510579009.7A CN105168373A (en) | 2015-09-13 | 2015-09-13 | Blood fat-reducing glossy privet fruit extract and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105168373A true CN105168373A (en) | 2015-12-23 |
Family
ID=54891138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510579009.7A Withdrawn CN105168373A (en) | 2015-09-13 | 2015-09-13 | Blood fat-reducing glossy privet fruit extract and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105168373A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105560348A (en) * | 2015-12-28 | 2016-05-11 | 吴芊葭 | Dichrocephala auriculata extract and medical application thereof in reducing blood fat |
| CN105942519A (en) * | 2016-04-27 | 2016-09-21 | 周飞燕 | Health-care food capable of reducing blood lipid and added with ginseng extract |
| CN110007031A (en) * | 2019-04-30 | 2019-07-12 | 南京海昌中药集团有限公司 | The fingerprint atlas detection method of the succus liquiritiae toast fruit of glossy privet |
-
2015
- 2015-09-13 CN CN201510579009.7A patent/CN105168373A/en not_active Withdrawn
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105560348A (en) * | 2015-12-28 | 2016-05-11 | 吴芊葭 | Dichrocephala auriculata extract and medical application thereof in reducing blood fat |
| CN105942519A (en) * | 2016-04-27 | 2016-09-21 | 周飞燕 | Health-care food capable of reducing blood lipid and added with ginseng extract |
| CN110007031A (en) * | 2019-04-30 | 2019-07-12 | 南京海昌中药集团有限公司 | The fingerprint atlas detection method of the succus liquiritiae toast fruit of glossy privet |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105168373A (en) | Blood fat-reducing glossy privet fruit extract and preparation method thereof | |
| CN105079308A (en) | Common rockvine herb extract as well as preparation method and pharmaceutical application of extract | |
| CN105030925A (en) | Plant extract for treating blood stasis disease and pharmaceutic preparation | |
| CN105911192B (en) | A kind of extracting method and fingerprint atlas detection method of Pterospermi Heterophylli active site promoting blood circulation and removing blood stasis | |
| CN105233022A (en) | Remote lemongrass herb extract and preparation method and medical appliance thereof | |
| CN105232619A (en) | Lysimachia trientaloides hemsl. extract as well as preparation method and medical application thereof | |
| CN104958333A (en) | Panax japonicus extract and medical application thereof | |
| CN105031070A (en) | Viola tricolor extract for treating gouty arthritis and preparation method thereof | |
| CN105147907A (en) | Dasheen flower extract, as well as preparation method and medicinal application thereof | |
| CN105079293A (en) | Cirald daphne bark extract, as well as preparation method and medical application thereof | |
| CN105125652A (en) | Tsinling larkspur root extract and preparing method and medical application thereof | |
| CN105055544A (en) | Plant extract capable of preventing brain aging | |
| CN105168305A (en) | Hungaian morningglory root extract for treating gouty arthritis | |
| CN105106276A (en) | Tradescantia extract as well as preparation method and medical application of tradescantia extract | |
| CN105232627A (en) | Solidago extract and preparation method and medical application thereof | |
| CN105030885A (en) | Sagina subulata extract for treating blood stasis and preparing method thereof | |
| CN104297360B (en) | A kind of detection method of Compound Xueshuantong preparation finger-print | |
| CN105560348A (en) | Dichrocephala auriculata extract and medical application thereof in reducing blood fat | |
| CN105125624A (en) | Euphorbia tithymaloides extract and preparing method and medical application thereof | |
| CN105079093A (en) | Wild chrysanthemum flower extract and medical application thereof for treating blood stasis disease | |
| CN105106274A (en) | Sabia schumanniana extract, preparing method thereof and medical application thereof | |
| CN106581087A (en) | Sabina chinensis leaf extract and preparation method and medical applications thereof | |
| CN108904566A (en) | The preparation method of flavones ingredient in a kind of FLOS CHRYSANTHEMI ALBA from Haizhou of China | |
| CN105535039A (en) | Japanese nanocnide herb extract and medical application thereof in treatment of gouty arthritis | |
| CN105106558A (en) | Brain aging resistance hosta ventricosa extract and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20151223 |